GO:0002060 purine nucleobase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002060 (purine nucleobase binding) is a molecular function describing the selective, non-covalent interaction of a protein or RNA with a purine base such as adenine, guanine, hypoxanthine, or xanthine [1,4,7].
• Purine nucleobase binding underlies nucleobase transport, purine salvage, riboswitch regulation, and methyltransferase cofactor recognition [1,3,5,6,7].
• The specificity of purine nucleobase binding is achieved through hydrogen bonding, aromatic stacking, and shape complementarity within a defined binding pocket [4,7,8].
• In protozoan parasites, purine nucleobase binding proteins such as NT3 mediate uptake of host purines and are regulated by RNA stem-loop structures [1,5].
• Dysregulation of purine nucleobase binding is linked to cancer, neurological disorders, and infectious diseases, making it a target for therapeutic intervention [3,5,8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable functional dissection of purine nucleobase binding proteins in disease-relevant contexts [1,5,7].
Description
Purine nucleobase binding (GO:0002060) is a molecular function defined as the binding to a purine nucleobase, an organic nitrogenous base with a purine skeleton [1,4]. This function is essential for numerous biological processes, including nucleobase transport, purine salvage, and the regulation of gene expression by riboswitches [1,5,6]. Proteins and RNAs that bind purine nucleobases are found across all domains of life, from protozoan parasites to humans, and their dysfunction is associated with a range of diseases [3,5,8]. The importance of purine nucleobase binding extends to drug discovery and biotechnology. For example, the purine-cytosine permease of Saccharomyces cerevisiae binds purine nucleobases with high specificity, and its activity is pH-dependent. In Leishmania donovani, the NT3 purine nucleobase transporter binds purines and its expression is regulated by a conserved RNA stem-loop. Additionally, S-adenosylmethionine (SAM)-binding riboswitches recognize purine nucleobases to control gene expression. Understanding the molecular details of purine nucleobase binding is therefore critical for developing novel therapeutics and for engineering biological systems [3,7,8]. Recent advances in structural biology and CRISPR-based genome editing have accelerated research into purine nucleobase binding proteins. Studies on H+-coupled nucleobase transport have revealed mechanistic insights into substrate recognition, while computational analyses of SAM interactions in methyltransferases have highlighted the role of purine nucleobase binding in cofactor specificity. These findings underscore the broad relevance of GO:0002060 in both basic and applied biomedical research [1,5,8].
purine nucleobase binding At A Glance
| GO ID | GO:0002060 |
|---|---|
| GO term | purine nucleobase binding |
| Ontology | molecular_function |
| Synonym | purine base binding, purine binding |
| Definition | Binding to a purine nucleobase, an organic nitrogenous base with a purine skeleton. |
| Major function | Selective recognition and non-covalent interaction with purine nucleobases such as adenine, guanine, hypoxanthine, and xanthine. |
| Related processes | Nucleobase transport, purine salvage, riboswitch regulation, methyltransferase cofactor binding. |
| Example proteins | Purine-cytosine permease (Saccharomyces cerevisiae), NT3 purine nucleobase transporter (Leishmania donovani), SAM-binding riboswitches. |
| Disease relevance | Cancer, neurological disorders, infectious diseases caused by protozoan parasites. |
What Is GO:0002060?
Purine nucleobase binding (GO:0002060) is the molecular function of selectively and non-covalently interacting with a purine nucleobase, which is an organic nitrogenous base containing a purine skeleton, such as adenine, guanine, hypoxanthine, or xanthine [1,4,7]. This binding event is typically mediated by hydrogen bonds, aromatic stacking interactions, and shape complementarity within a binding pocket, and it is essential for processes like nucleobase transport, purine salvage, and riboswitch regulation [4,5,6,7].
Why Is purine nucleobase binding Important in Cell Biology?
Purine nucleobase binding is fundamental to cellular metabolism and gene regulation, as it governs the uptake, salvage, and sensing of purines, which are essential building blocks for DNA, RNA, and cofactors such as ATP and SAM [1,4,6]. Dysregulation of purine nucleobase binding proteins is implicated in cancer, neurological disorders, and infectious diseases, making this function a promising target for therapeutic intervention [3,5,8]. Moreover, understanding the structural basis of purine recognition informs the design of drugs and biotechnological tools.
• Enables purine salvage pathways that recycle nucleobases for nucleotide synthesis [1,4].
• Mediates nucleobase transport across membranes in protozoan parasites and fungi [4,5,7].
• Controls gene expression through purine-responsive riboswitches.
• Regulates methyltransferase activity by binding SAM, a purine-containing cofactor.
• Influences drug sensitivity and resistance in cancer and infectious diseases [5,8].
• Provides targets for antiparasitic and anticancer drug development [5,7].
• Facilitates metabolic engineering of purine-dependent pathways [1,4].
• Serves as a model for studying molecular recognition and specificity [7,8].
Molecular Mechanism of purine nucleobase binding
Substrate recognition and binding pocket
In simple terms: The protein or RNA has a pocket that fits purine bases like a lock and key.
Purine nucleobase binding proteins and RNAs possess a binding pocket that selectively recognizes purine bases through hydrogen bonding and aromatic stacking. For example, the purine-cytosine permease of Saccharomyces cerevisiae binds purine nucleobases with high specificity, and this binding is influenced by external pH. Similarly, the NT3 purine nucleobase transporter of Leishmania donovani binds purines, and its expression is regulated by a conserved RNA stem-loop. Structural studies on H+-coupled nucleobase transport have revealed key residues involved in substrate recognition.
Conformational changes upon binding
In simple terms: When the base binds, the protein changes shape to hold it tightly.
Binding of purine nucleobases often induces conformational changes in the protein or RNA that stabilize the complex and facilitate downstream functions. For instance, SAM-binding riboswitches undergo structural rearrangements upon binding to purine nucleobases, which modulate gene expression. In methyltransferases, the interaction with SAM involves specific signatures that are critical for cofactor binding and catalysis. These conformational dynamics are essential for the biological activity of purine nucleobase binding proteins [3,6].
Cofactors and metal ions
In simple terms: Some helper molecules or ions assist in the binding process.
Certain purine nucleobase binding proteins require cofactors or metal ions for optimal binding. For example, the interaction of tri-cyclic nucleobase analogs with xanthine oxidase and purine nucleoside phosphorylase involves specific cofactor interactions that influence enzyme activity. Additionally, SAM-dependent methyltransferases rely on the purine moiety of SAM for binding, and this interaction is modulated by the presence of metal ions in some cases.
Regulation by RNA elements
In simple terms: RNA switches can control how much protein is made in response to purine levels.
In some organisms, purine nucleobase binding is regulated by RNA elements such as riboswitches or stem-loop structures. For example, the purine-responsive expression of the Leishmania donovani NT3 purine nucleobase transporter is mediated by a conserved RNA stem-loop. Similarly, an RNA-binding protein complex regulates the purine-dependent expression of a nucleobase transporter in trypanosomes. These RNA-based regulatory mechanisms allow cells to adapt to changes in purine availability [1,5].
Specificity and affinity determinants
In simple terms: The shape and chemical groups of the base determine how tightly it binds.
The specificity and affinity of purine nucleobase binding are determined by the chemical complementarity between the base and the binding pocket. Studies on nucleoside-driven specificity of DNA methyltransferases have shown that even subtle differences in the purine base can affect binding and catalysis. Computational analyses of SAM interaction signatures in methyltransferases have further elucidated the molecular determinants of purine recognition. These insights are valuable for designing inhibitors or substrates with altered specificity [2,3].
Key Genes Involved in GO:0002060 purine nucleobase binding
The following genes and proteins are representative examples of purine nucleobase binding function, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCY2 | Purine-cytosine permease in Saccharomyces cerevisiae | Model for pH-dependent nucleobase transport and binding |
| NT3 | Purine nucleobase transporter in Leishmania donovani | Regulated by RNA stem-loop; drug target for leishmaniasis |
| XRCC1 | DNA repair protein with purine nucleobase binding activity | Implicated in cancer and DNA damage response |
| PNP | Purine nucleoside phosphorylase | Purine salvage enzyme; target for T-cell malignancies |
| XDH | Xanthine dehydrogenase/oxidase | Purine metabolism; interacts with nucleobase analogs |
| SAM riboswitch | RNA element that binds SAM | Regulates gene expression in bacteria |
| AdeB | Adenine deaminase | Purine salvage in parasites |
| HPRT1 | Hypoxanthine phosphoribosyltransferase | Purine salvage; mutations cause Lesch-Nyhan syndrome |
| APRT | Adenine phosphoribosyltransferase | Purine salvage; deficiency causes kidney stones |
| ADA | Adenosine deaminase | Purine metabolism; deficiency causes SCID |
| GART | Phosphoribosylglycinamide formyltransferase | Purine biosynthesis |
| MTHFD1 | Methylenetetrahydrofolate dehydrogenase | Purine synthesis; cancer relevance |
| MAT2A | Methionine adenosyltransferase | SAM synthesis; purine nucleobase binding |
| DNMT1 | DNA methyltransferase 1 | SAM-dependent; nucleoside-driven specificity |
| DNMT3A | DNA methyltransferase 3A | SAM binding; cancer and developmental disorders |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase 1 | Purine synthesis; neurological disorders |
| IMPDH2 | Inosine monophosphate dehydrogenase 2 | Purine synthesis; immunosuppression target |
How Is purine nucleobase binding Regulated?
Purine nucleobase binding is regulated at multiple levels, including RNA-based mechanisms and protein-protein interactions. In trypanosomes, an RNA-binding protein complex regulates the purine-dependent expression of a nucleobase transporter, allowing adaptation to purine availability. Similarly, in Leishmania donovani, a conserved RNA stem-loop mediates purine-responsive expression of the NT3 transporter. Additionally, the binding of SAM to riboswitches controls gene expression in response to purine levels. These regulatory circuits ensure that purine nucleobase binding proteins are expressed and active only when needed, and their dysregulation can contribute to disease [1,5,6].
purine nucleobase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HPRT1 | Lesch-Nyhan syndrome | Knockout mice, patient-derived iPSCs |
| PNP | T-cell immunodeficiency | Knockout mice, cell lines |
| DNMT3A | Acute myeloid leukemia | Knock-in mice, CRISPR point mutation |
| NT3 | Leishmaniasis | Leishmania knockout, overexpression |
| XDH | Gout, hyperuricemia | Knockout mice, enzyme assays |
Purine nucleobase binding in cancer
Altered purine metabolism and nucleobase binding are hallmarks of many cancers. For example, SAM-dependent methyltransferases such as DNMT1 and DNMT3A rely on purine nucleobase binding for their activity, and their dysregulation leads to aberrant DNA methylation patterns associated with tumorigenesis [2,3]. Additionally, purine salvage enzymes like PNP and XDH are targets for anticancer therapies, as their inhibition can selectively kill cancer cells.
Purine nucleobase binding in neurological disorders
Defects in purine nucleobase binding and salvage are linked to neurological disorders. Mutations in HPRT1, which encodes a purine salvage enzyme, cause Lesch-Nyhan syndrome, characterized by severe neurological impairment. Similarly, PRPS1 mutations lead to neurological disorders such as Arts syndrome. These conditions highlight the critical role of purine nucleobase binding in brain function.
Purine nucleobase binding in infectious diseases
Protozoan parasites such as Leishmania and Trypanosoma depend on purine nucleobase binding for survival, as they cannot synthesize purines de novo. The NT3 transporter in Leishmania donovani binds purine nucleobases and is essential for parasite viability, making it a promising drug target. Similarly, the purine-cytosine permease in Saccharomyces cerevisiae serves as a model for studying antifungal drug interactions.
From purine nucleobase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of purine nucleobase binding affect cell viability? | CRISPR knockout of target gene in cell lines |
| Does a specific point mutation alter substrate specificity? | CRISPR point mutation knock-in |
| Can a tagged version of the protein be used for localization studies? | CRISPR knock-in of fluorescent tag |
| Does overexpression of the transporter increase purine uptake? | CRISPR overexpression (e.g., CRISPRa) |
| What is the effect of a disease-associated mutation on binding affinity? | CRISPR knock-in of patient mutation |
| Can a purine analog inhibit parasite growth? | CRISPR knockout of transporter in Leishmania |
How to Study the purine nucleobase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry (ITC) | Binding affinity and thermodynamics | Characterize purine nucleobase binding to proteins |
| Surface plasmon resonance (SPR) | Kinetics of binding | Screen inhibitors of purine nucleobase transporters |
| X-ray crystallography | 3D structure of binding pocket | Design drugs targeting purine nucleobase binding |
| CRISPR knockout | Loss-of-function phenotype | Determine essentiality of purine nucleobase binding genes |
| CRISPR knock-in | Tagged or mutant protein expression | Study localization and disease mutations |
| RNA-seq | Transcriptional changes | Identify downstream effects of purine nucleobase binding |
| Ribosome profiling | Translation efficiency | Measure changes in protein synthesis upon purine availability |
| Molecular dynamics simulations | Atomic-level interactions | Predict binding modes and specificity |
Biochemical binding assays
Direct measurement of purine nucleobase binding can be achieved using isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), or fluorescence polarization. These methods provide quantitative data on binding affinity and specificity, as demonstrated for the purine-cytosine permease and NT3 transporter.
Structural biology
X-ray crystallography and cryo-electron microscopy can resolve the atomic details of purine nucleobase binding pockets. For example, structural studies on H+-coupled nucleobase transport have revealed key residues involved in substrate recognition. These structures inform drug design and mechanistic understanding.
Genetic and genomic approaches
CRISPR-based knockout, knock-in, and point mutation models allow functional dissection of purine nucleobase binding proteins in cells and organisms. RNA-seq and ribosome profiling can reveal downstream effects on gene expression, as shown for the RNA-binding protein complex regulating nucleobase transporter expression.
Computational modeling
Molecular dynamics simulations and docking studies can predict how purine nucleobases interact with proteins and RNA. Computational analyses of SAM interaction signatures in methyltransferases have provided insights into cofactor specificity, and similar approaches can be applied to other purine nucleobase binding proteins.
How CRISPR Can Be Used to Study GO:0002060 purine nucleobase binding
Knockout
CRISPR knockout of genes encoding purine nucleobase binding proteins, such as NT3 in Leishmania or FCY2 in yeast, can reveal their essentiality and role in purine uptake and metabolism [4,5]. Knockout cell lines are valuable for drug sensitivity assays and for identifying compensatory pathways.
Point Mutation
Introducing specific point mutations in the binding pocket of purine nucleobase binding proteins via CRISPR can dissect the contribution of individual residues to substrate specificity and affinity. For example, mutations in the SAM-binding pocket of DNMT3A can alter methylation activity [2,3].
Knock-in
CRISPR knock-in of fluorescent tags or epitope tags into endogenous loci allows real-time visualization and biochemical purification of purine nucleobase binding proteins. This approach has been used to study the localization of NT3 in Leishmania and to track purine transporters in live cells.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression can increase the levels of purine nucleobase binding proteins, enabling studies of their effects on purine homeostasis and gene expression. Overexpression of the purine-cytosine permease in yeast has been used to study pH-dependent transport.
How EDITGENE Supports purine nucleobase binding Research
Researchers studying purine nucleobase binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as purine transport, drug resistance, or disease progression. CRISPR-based genome editing provides a precise and efficient way to create knockout, point mutation, knock-in, and overexpression models in relevant cell types, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for purine nucleobase binding research.
Frequently Asked Questions About purine nucleobase binding
What is purine nucleobase binding?
Purine nucleobase binding (GO:0002060) is the molecular function of selectively and non-covalently interacting with a purine nucleobase, such as adenine or guanine, which is essential for processes like nucleobase transport and purine salvage [1,4,7].
What genes are involved in purine nucleobase binding?
Genes encoding purine nucleobase binding proteins include FCY2 in yeast, NT3 in Leishmania, and HPRT1, PNP, and XDH in humans [4,5,8].
How is purine nucleobase binding regulated?
It can be regulated by RNA elements such as riboswitches and stem-loops, as well as by protein-protein interactions and metabolic feedback [1,5,6].
What diseases are associated with purine nucleobase binding?
Dysregulation is linked to cancer, neurological disorders like Lesch-Nyhan syndrome, and infectious diseases such as leishmaniasis [1,2,5,8].
What methods are used to study purine nucleobase binding?
Common methods include ITC, SPR, X-ray crystallography, CRISPR knockout/knock-in, RNA-seq, and molecular dynamics simulations [3,4,5,7].
Can CRISPR be used to study purine nucleobase binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional studies of genes involved in purine nucleobase binding [1,5,7].
What is the role of purine nucleobase binding in parasites?
In parasites like Leishmania and Trypanosoma, purine nucleobase binding is essential for scavenging host purines, making these proteins drug targets [1,5].
How does pH affect purine nucleobase binding?
The purine-cytosine permease of Saccharomyces cerevisiae shows pH-dependent nucleobase uptake and binding, with optimal activity at specific pH ranges.
What are the structural features of purine nucleobase binding pockets?
Binding pockets typically contain aromatic residues for stacking and hydrogen bond donors/acceptors for specific recognition of the purine base [7,8].
Why is purine nucleobase binding important for drug discovery?
It is a target for antiparasitic, anticancer, and immunosuppressive drugs, as inhibition can disrupt essential metabolic pathways [5,8].
Conclusion
Purine nucleobase binding (GO:0002060) is a fundamental molecular function that governs purine transport, salvage, and gene regulation across diverse organisms. Its dysregulation is implicated in cancer, neurological disorders, and infectious diseases, making it a compelling target for therapeutic development. Advances in CRISPR genome editing and structural biology continue to unravel the mechanistic details of purine recognition, offering new opportunities for drug discovery and biotechnology. Researchers can leverage EDITGENE's CRISPR models and services to accelerate their studies on purine nucleobase binding and related pathways.
References
- 1. Rico-Jiménez M et al.. 2021. An RNA-binding protein complex regulates the purine-dependent expression of a nucleobase transporter in trypanosomes.. Nucleic Acids Res 49(7):3814-3825 PMID: 33744953
- 2. Gade M et al.. 2023. Nucleoside-Driven Specificity of DNA Methyltransferase.. Chembiochem 24(22):e202300094 PMID: 37548117
- 3. Kadam MS et al.. 2024. S-adenosyl-l-methionine interaction signatures in methyltransferases.. J Biomol Struct Dyn 42(6):3166-3176 PMID: 37261836
- 4. Brèthes D et al.. 1992. Purine-cytosine permease of Saccharomyces cerevisiae. Effect of external pH on nucleobase uptake and binding.. Eur J Biochem 210(3):785-91 PMID: 1483463
- 5. Licon MH et al.. 2020. Purine-responsive expression of the Leishmania donovani NT3 purine nucleobase transporter is mediated by a conserved RNA stem-loop.. J Biol Chem 295(25):8449-8459 PMID: 32354744
- 6. Batey RT. 2011. Recognition of S-adenosylmethionine by riboswitches.. Wiley Interdiscip Rev RNA 2(2):299-311 PMID: 21957011
- 7. Weng J et al.. 2023. Insight into the mechanism of H(+)-coupled nucleobase transport.. Proc Natl Acad Sci U S A 120(33):e2302799120 PMID: 37549264
- 8. Stachelska-Wierzchowska A et al.. 2024. Interaction of Tri-Cyclic Nucleobase Analogs with Enzymes of Purine Metabolism: Xanthine Oxidase and Purine Nucleoside Phosphorylase.. Int J Mol Sci 25(19) PMID: 39408755
